Filing Flows › Harvard Bioscience (HBIO) › Q2 2026
Harvard Bioscience (HBIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Harvard Bioscience (HBIO) reported revenue of $22.7M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +10% from the quarter before. Operating margin was -4.3%, net loss $2.9M (12.8% of revenue).
Harvard Bioscience, Q2 2026: revenue $22.7M (+11% year over year), operating margin -4.3%, net loss $2.9M, operating cash flow $325K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.7M | +10% | +11% |
| Operating profit | −$978K | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | $325K | — | -88% |
What changed
Revenue was $22.7M in Q2 2026, up 11% year over year and up 10% from the previous quarter. Instruments, Equipment, Software, and Accessories was the largest line at 89% of revenue. Instruments, Equipment, Software, and Accessories added $2.1M year over year (up 12%), 93% of the total change.
Gross margin was 55.6%, down 0.8 points from Q2 2025. Operating costs exceeded revenue by $1.0M, an operating margin of -4.3%. Operating expenses grew 10% against revenue growth of 11%. The fastest-growing cost line was Sales & marketing (+19%). The quarter ended with a net loss of $2.9M, narrower than the previous quarter's $3.4M loss. Net interest and other expense of $1.9M was the main reason.
Operating cash flow was $325K (down 88% year over year). Non-cash charges added back $1.3M of depreciation and amortization and $380K of share-based compensation. Working capital and other items added $1.6M. Capital expenditures of $688K exceeded it, leaving free cash flow of −$363K.
Questions
What was Harvard Bioscience's revenue in the second quarter 2026?
Harvard Bioscience (HBIO) reported revenue of $22.7M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +10% from the quarter before.
Was Harvard Bioscience profitable in the second quarter 2026?
Operating loss was $978K (-4.3% of revenue) and net loss $2.9M.
Source: Harvard Bioscience 10-Q on SEC EDGAR.